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Abstract 
 
Objectives 
This  paper seeks to highlight from a UK perspective the current lack of a research evidence base in 
paediatric palliative care  that has resulted in a paucity of available medicines with appropriate 
formulations (strength and dosage form) to provide symptom management for children with life-
limiting illnesses and to raise awareness of this group of “therapeutic orphans”.  Currently, clinicians 
have limited, often unsuitable medication choices for their paediatric palliative care patients, with 
little hope of moving away from the status quo. 
Key findings 
Most medicines used in children receiving palliative care are old and off-patent drugs, developed for 
and tested in an adult population. Many are not available in suitable formulations (dosage form and 
strength) for administration to children and there are often no age-related profiles of adverse drug 
reactions or for safe dosing.  
Summary 
Existing regional paediatric palliative care networks and support organisations should lobby funding 
bodies and the academic community to support appropriate research for this group of therapeutic 
orphans. Support must also be provided to pharmaceutical companies in the development of 
suitable products with appropriate formulations.   
 
Key papers Findings 
Shirkey H.  Therapeutic Orphans.  Editorial 
Comment. Paediatrics 1999; 104(3): 583-4. 
Shirkey drew attention to the fact that the 
problem of lack of paediatric medicines is not 
solely the responsibility of the drug industry but 
must include the government, academic 
paediatric centres, and practicing clinicians. 
Conroy S et al. Survey of unlicensed and off 
label drug use in paediatric wards in European 
countries. European Network for Drug 
Investigation in Children. BMJ 2000; 320: 79-82.  
A ground-breaking paper which found that the 
use of off label or unlicensed drugs to treat 
children is widespread. 
Wong I et al. Paediatric medicines research in 
the UK: how to move forward?  Curr Opinion 
Drug Safety 2003; 26(8):529-37. 
Highlighted that a wide range of study designs 
are available but are probably under-used in 
PPC research.  
Nunn T, Williams J.  Formulation of medicines 
for children.  Brit J Clin Pharmacol 2005; 59(6): 
674-6. 
Highlighted that there are many gaps in our 
knowledge about paediatric formulations and 
many challenges for the industry if suitable 
preparations are to be available for all ranges.  
Tomlinson D et al. Challenges to participation in 
paediatric palliative care research: a review of 
the literature. Palliat Med 2007; 21:435–440. 
Key elements that may maximize completion of 
research and obtain a more representative 
sample include obtaining the opinions on study 
design and interview script from experienced 
families and maximizing the partnership 
between health care professionals and the 
research team. 
Spathis A et al. Learning from paediatric 
palliative care: Lessons for adult practice.  
Palliat Med 2012 26: 777 
Discusses how paediatric palliative care has 
evolved to need novel/better drug delivery 
options. 
Beecham E et al.  Pharmacological interventions 
for pain in children and adolescents with life-
limiting conditions. Cochrane Database of 
Systematic Reviews. 2015; 3: CD010750. 
Highlighted the paucity of research in 
paediatric pain management. 
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Palliative care in adults and children with Life-limiting illnesses (LLI)  
An editorial entitled UK: The Best Place in the World to Die stated that the UK ranks first in the 2015 
Quality of Death Index, a measure of the quality of palliative care in 80 countries around the world 
released by The Economist Intelligence Unit (EIU).[1]  The United Kingdom is a world leader in terms 
of the provision of palliative care. “The exemplary features include a national policy framework for 
palliative care, relatively high levels of healthcare expenditure, good training in specialist and 
generalist palliative care, financial subsidies (from the charitable sector in the case of the UK), 
availability of opioids, and public awareness of palliative care. However, within the UK, there are 
notable failings”. The report highlights examples of poor symptom control at the end of life.  NICE 
clinical guidelines to support adults at the end of life have been available since 2011, but similar NICE 
guidelines for infants, children and young people are not anticipated to be released until late 2016. 
Another issue of concern in paediatric palliative care is that National Health Service funding 
provision for paediatric palliative care is poor compared to other paediatric disciplines with much of 
the care provided by third sector organisations, who rely on charitable funds for around 90% of their 
income. 
 
The UK is the birthplace of hospice care for children and paediatric palliative care (PPC), which is a 
recognised clinical subspecialty of paediatrics. Palliative care for children is defined as an active and 
total approach to care, embracing physical, emotional, social and spiritual elements. Specialist 
palliative care services for children may be delivered in a variety of settings, such as hospices, 
tertiary children’s hospitals, and within community-based services. In contrast to adult palliative care 
, oncology diagnoses make up only a small proportion of cases, with over 300 conditions recognised 
among the paediatric palliative population.[2] This case load diversity means that palliative care 
practitioners must manage a wide range of complex symptoms.[3]   
 
Challenges in paediatric palliative care 
The number of children with life limiting and life threatening conditions is not insignificant, with an 
estimated number of almost 50,000 infants, children and young people aged 19 years or under in 
the UK (40,000 of these in England) living with a life-limiting condition and who may require 
palliative care.  This figure is rising year on year.[4] 
 
These children and young people have unique palliative care needs, which often differ to those of 
adults.[5] These differences include: 
 
 The wide range of underlying conditions, many of which are individually rare diseases 
 The limited paediatric evidence base available for many of the therapeutic interventions 
 The use of routes of administration which are less commonly encountered in general 
paediatrics (such as transmucosal, transdermal, and subcutaneous infusion)  
 The need for smaller doses, without availability of suitable dosage forms. 
 
Additional challenges, that are similar to adult patients, include: 
 the need to provide care  in a choice of setting (home, hospice, hospital) 
 medication regimes which often have to be administered by non-medical carers. 
 
Clinicians need appropriate medicines to prescribe that are both effective and easy to administer by 
parents and carers in different settings, including rapidly effective, needle free medication for 
breakthrough symptoms such as pain and nausea.[6]  Children represent a variable and diverse 
subset of individuals from the neonate through to a young adult and factors that influence 
prescribing are distinct from adults. Physical development and age influence both drug effect and 
drug disposition, with age-related changes in pharmacokinetics and pharmacodynamics. Neonates, 
for example, have inefficient renal filtration, relative enzyme deficiencies, differing target organ 
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sensitivity and inadequate detoxifying systems, which cause delayed excretion. They have reduced 
gastric emptying which can make the oral route less reliable, but transdermal absorption is greatly 
increased so there is a greater risk of undesired exposure, and hence toxicity, via this route than in 
older children or adults.[7] 
 
The issue of Infants and children becoming “therapeutic or pharmaceutical orphans” was first raised 
by Shirkey back in 1968:  “ …many of the drugs released since 1962 carry an ‘orphaning’ clause, eg, 
‘Not to be used in children . . . is not recommended for use in infants and young children since few 
studies have been conducted in this age group . . . clinical studies have been insufficient to establish 
any recommendations for use in infants and children . . . should not be given to children.”   However, 
many clinicians prescribe medicines as off-label or unlicensed medicines to meet the health needs of 
children.  
 
  Paediatric palliative care medicinesThe classes of medication most commonly used in palliative 
care are: analgesics, anti-emetics, laxatives/aperients, adjuvant medications, steroids, 
antidepressants and other neuroleptic medications and sedatives.  
  
Issues with paediatric palliative care medicines 
Although many of the problems with medicines for use in paediatric palliative care are similar to 
those in the field of paediatric medicines generally, palliative care represents a very relevant 'case 
study' for the reasons described below.  Notwithstanding the fact that some of these issues have 
already been identified, this paper seeks to synthesise the contributing factors and highlight what 
progress has been made so far and what still needs to be done in this field.  
 
There is a limited evidence base available for many of the therapeutic interventions in paediatric 
palliative care. For example, there is a paucity of data to guide clinicians in the use of 
pharmacotherapy for management of respiratory symptoms [8] and, although the number of 
analgesics available for managing pain has increased significantly over the last decade, the research 
evidence for the efficacy and safety of these drugs for children is limited.[9]   
 
Although an evidence-based approach is essential, limited research in PPC demands that much of 
the evidence is extrapolated from adult studies.[10]  These are often conducted in specific disease 
groups, with little relevance to the paediatric population.[8]   For example, reports on chronic pain 
are generally from case series, with few controlled trials in children and almost all chronic pain 
interventions have been adapted from their use in adult chronic pain.  This paucity of research in 
paediatric pain management was highlighted in a recent Cochrane review.[11] The World Health 
Organisation Guidelines on the Pharmacological Treatment of Persisting Pain in Children with 
Medical Illnesses acknowledges that there is a need for research into paediatric pain management 
[page 10] and the Guideline Development Group calls upon the scientific community to invest in 
clinical research on the safety and efficacy of pain-relieving medicines specifically in children with 
persisting pain due to medical illness. [12] 
 
As a direct consequence of limited paediatric research, a number of significant issues with 
prescribing for this population persist, and are discussed below. 
 
Existing medicines 
Most medications used in children in palliative care are not protected by a patent and are in the 
generic domain. 
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Off label 
Many of the drugs used routinely in adult palliative care are unlicensed for use in children or need to 
be prescribed outside the terms of the product license.[13] The risks and benefits of these drugs in 
children have not been scrutinized by the licensing body, so there are often no age-related profiles 
of adverse drug reactions or dosing, and medication may not be available in appropriate strengths 
and dosage forms for a child. Despite this, there is often huge practical experience of the use of 
some of these drugs in specialist PPC centres in the UK [7], yet such experience remains to be 
systematically collected and analysed. However, some clinicians can be wary of using off-licence 
medicines for children for fear of litigation if adverse events occur and regulatory bodies require 
robust data from pharmaceutical companies to enable licensing in younger age groups.[14] 
 
The use of off-label or unlicensed medicines in children not only causes difficulties for prescribers 
and pharmacists, but there has also been evidence of harm. The level of evidence published on the 
harm from off label and unlicensed medicines use in children is scarce but there is sufficient 
evidence that harm actually occurs and is underreported.[15] 
 
Lack of familiarity of drugs and doses used in paediatric palliative care by healthcare professionals 
Various healthcare professionals in primary, secondary and tertiary services are involved in the care 
of PPC patients and not all will be familiar with the drugs and doses used. This creates additional 
difficulty when prescribing also involves the use of unlicensed or off-label medication and where 
reliable information in relation to prescribing these medications is not available. From a practical 
perspective, reliable information in relation to prescribing of unlicensed/off-label medicines needs 
to be shared across the interface of primary, secondary and tertiary care, particularly as paediatric 
palliative care is such a specialist and high risk area.   This would allow GPs to prescribe safely in the 
community and have the knowledge in relation as obtaining some medications.  
 
The Association for Paediatric Palliative Medicine Master Formulary, first published in January 2011, 
and recently updated, was the first significant attempt to share the current ‘best knowledge 
available’ by collating the existing evidence base and, in its absence, a significant body of 
professional experience. The formulary provides information on indications, routes and standardised 
doses used in paediatric palliative care .  Some guidance on the legalities of prescribing unlicensed 
and off-label medication is provided by the MHRA (2009). [16]   
  
Formulations 
Paediatric formulations must allow accurate administration of the dose to children of widely varying 
age and weight. The development of age-adapted clinically relevant dosage forms and taste-masking 
of aversive orally administered drugs are formidable challenges for formulation scientists.[17,18] 
Compliance issues arise where children refuse medication due to its formulation, volume, taste, and 
appearance.[7] 
 
Challenges for industry in the development of preparations that are suitable across all age ranges in 
paediatrics include: 
• acceptable dose volumes and sizes 
• safety, e.g. risk of aspiration or choking for solid dosage forms 
 administration routes 
• excipient tolerability and safety 
• palatability  
 
These challenges are amplified in regard to drugs used predominately in palliative care, where the 
paediatric population is far too small to be economically appealing.  
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Administration 
Administering medications to children should be as simple and non-traumatic as possible. For 
example, children may not report breakthrough pain if they suspect that a needle will follow.[6] 
Medicines are often administered in the community by parents or informal carers where the route 
of administration may need to be different to, but equally as effective as, what may be used in a 
hospital- based acute care situation. The lack of available safe, effective and easy to administer 
medications  may limit the care that can be supported in the community and may be the very issue 
that forces parents to give up on their preferred place of care. 
 
Delivery 
Over the last 5-10 years there has been an increase in the development of new delivery systems for 
drugs, e.g. through intranasal, oral transmucosal (buccal/ sublingual) and transdermal routes.  Many 
of the dosage forms designed for adults, such as oro-dispersible tablets, buccal gels and transdermal 
patches, would also benefit children if they were available in an appropriate paediatric dose.  
 
Many children in the PPC setting receive medication via enteral feeding tubes. However, very little 
accurate information is available regarding this route of drug administration. Not all liquids are 
suitable for tube administration.[19]  For example, Zomorph® is in capsules with fixed doses, making 
small increments difficult, and there is no data regarding the suspension of the granules in water, for 
administration via the tube.   The manufacturer of MST granule sachets also has no data in relation 
to suspension and manufacturers are unable to endorse anything that is outside their license.  Due 
to a lack of appropriate alternatives, many PPC clinicians have to prescribe granules or capsules to 
be opened and dispersed in water, despite the huge issue around dose uniformity via this method.  
The Handbook of Drug Administration via Enteral Feed tubes, although not specific to paediatrics, is 
one example of sharing best practice and the book covers the technical, practical and legal aspects 
that need to be considered before prescribing or administering drugs via enteral feeding tubes.[20] 
 
Mixing drugs in a syringe driver for subcutaneous (SC) infusion is standard practice in palliative care.  
However there is very little data on the use of this route in children and the marketing authorisation 
for many of the injectable drugs used does not specifically cover SC administration.  This practice 
should be better supported by stability data, as doses and concentrations used vary more widely 
that in the adult setting. Some evidence for practice, and information based on a body of clinical 
experience, can be found in ‘The Syringe Driver: Continuous subcutaneous infusions in palliative 
care’ (and on Palliativedrugs.com), but this information relates to adult, rather than paediatric, 
practice. [21] 
 
The oral transmucosal route via sublingual and buccal administration of medication, provides a route 
which is relatively non-invasive and independent of enteral absorption.[22] It is relatively simple to 
teach to non-medical carers and gives fast onset of action, making it very attractive for the rapid 
treatment of breakthrough symptoms.  The doses are likely to differ from oral doses as the route 
avoids first pass metabolism. The dosage forms are well tolerated, may be preferable to the nasal 
route for some parents and children, and does not need input from the child if they are drowsy or 
poorly able to cooperate. However there are very few licensed preparations suitable for children, 
and much current use is of parenteral liquids off label.  
 
Transdermal delivery systems (TDDS) are an attractive option in paediatrics as they are one of the 
least invasive routes of administration. The use of TD hyoscine hydrobromide, for example, is 
relatively common place in paediatrics for the management of secretions. Fentanyl and 
buprenorphine patches are also available, and can be very useful for the management of stable pain 
in palliative care. However, paediatric patients often require different doses than are commercially 
available as the patch size is usually governed by adult dosing. Alteration of the patch size, either by 
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cutting or by obscuring part of the area of contact with the skin, may allow for administration of 
smaller doses. However, reservoir patches cannot be cut (as the content will leak out) and with 
matrix patches there is no guarantee of even drug distribution throughout the matrix or that the 
leakage will not occur across the cut surface. The cutting of patches therefore remains an unlicensed 
and unrecommended practice.[23]  
 
Dosing 
Existing preparations do not generally allow for small doses or small incremental changes in dose (eg 
transmucosal lozenges, large transdermal patches, tablets which cannot be suspended/dissolved or 
designed to be halved or quartered).  However, the lack of appropriate dose preparations often 
necessitates the manipulation of medications, for example the suspension of capsules in water so 
that a proportionate dose can be given. Stability data or estimates of dose accuracy in regard to 
manipulated drugs is rarely available from manufacturers, who will not advocate or support this 
practice.   
 
Financial considerations 
Funding in palliative care, both for clinical services and research activity, is relatively low and likely to 
be even lower in the paediatric population.  The National Cancer Research Institute (NCRI) Cancer 
Research Database shows that since its inception in 2002 the funding for cancer-related palliative 
and end of life care research has been consistently below 0.7% of the total spent on cancer research 
in the UK. No data are available on spend in palliative and end of life care research in non-cancer 
conditions, but this is likely to be even lower.[24]   
 
In general, the cost of medication preparations most suited to children, such as TD patches, oral 
transmucosal and liquid preparations, is higher than those of standard adult tablet formats.  The 
prescribing of liquid preparations, which are mostly specials1 unlicensed medicines and are 
expensive, may not be supported by Clinical Commissioning Groups (CCGs replaced Primary Care 
Trusts in 2013).  The cost of these medications is largely unregulated and therefore prices, as well as 
local prescribing agreements, vary significantly.    
 
Why is there a lack of research and investment in this area? 
There is clearly a need for well-designed paediatric studies with objective outcome measures which 
test the efficacy of an intervention and also the impact on quality of life. The relatively small 
numbers of children receiving palliative care in the UK, and the diversity of medical conditions within 
this group, adds an additional challenge in terms of recruiting sufficient numbers, so multi-centre 
studies will be essential. There are also ethical and logistical dilemmas associated with clinical 
studies in children and for this reason companies seeking registration of medicines may not regard 
drug testing in children as viable or profitable.[25]  
 
Formulation research has the know-how and infrastructure to develop appropriate dosage forms 
and medications for this group of children, to optimise therapeutic interventions.  However, 
research funding bodies, such as the National Institute for Health Research in England, do not fund 
formulation research as it is regarded as basic science rather than patient centric translational 
research.  Other funding bodies may not be interested in funding formulation research as it is 
perceived as ‘low tech’ and will not lead to a scientific breakthrough. Thus, there is no real financial 
incentive for academics to conduct this research.  
 
                                                          
1 A medicine manufactured by a specials manufacturer holding a Manufacturer’s specials Licence (MS) in multiple quantities with end 
product analytical testing; A special medicine produced by a specials manufacturer holding a MS as a bespoke medicine without end 
product analytical testing; Extemporaneously prepared medicines - Unlicensed medicines made in a pharmacy under a pharmacist’s 
direct supervision 
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Back in 1999 Shirkey commented that the problem is not solely the responsibility of the drug 
industry but must include the government (especially the Food and Drug Administration), academic 
paediatric centres, and practicing clinicians. Pharmaceutical firms struggle to find a sufficient 
number of clinical investigators with interest, experience, and patients for the study of new drugs. 
These difficulties are inversely proportional to the frequency of the disease and to the age and size 
of the patient.  However, it is feasible.  The Food and Drug Administration has statutory 
responsibility for ensuring that drugs are safe and effective and it must have the same criteria for 
the study of drugs for infants and children as for adults.  Present regulation of human 
experimentation makes drug testing difficult. The Food and Drug Administration recognizes the 
responsibility of industry to provide adequate directions and accurate dosage for use of drugs in 
children; likewise, it recognises the difficulties involved in obtaining this information. In order to 
have drugs of better efficacy and safety for children, those responsible for providing PPC will have to 
assume the responsibility for developing active programmes of clinical pharmacology and drug 
testing in infants and children, or just accept the status of “Therapeutic Orphans” for their 
patients.[26]  
 
What has been done?  
The Better Medicines for Children Initiative in the EU and Best Pharmaceutical for Children Act in the 
US sought to improve the availability of appropriate medicines for children by increasing funding and 
providing incentives for the pharmaceutical industry to tackle the problem. These initiatives have 
significantly improved the research and availability of licensed new medicines for most children.  
 
A ground-breaking paper on the unlicensed use of medicines in children became a catalyst for the 
development of subsequent research and regulatory initiatives in both the US and EU.[27]  
 
A European regulation, the Regulation of the European Parliament and of the Council on Medicinal 
Products for Paediatric Use, has been developed and accepted by the European Commission.[28]  
This established requirements and incentives aimed at satisfying the need for medicines that are 
appropriately formulated and authorised for the treatment of children.  This legislation became law 
in January, 2007.  The introduction of the paediatric investigation plan (PIP) ensured that the 
development of medicinal products that are potentially to be used for the paediatric population 
becomes an integral part of the development of medicinal products, integrated into the 
development programme for adults. 
 
Eighty percent of the twenty FP7 funded paediatric medicines projects in the EU programme are 
developing new formulations and dosage forms of medicines specifically for the paediatric 
population and some of these could potentially be useful in palliative care . [29]  
 
The World Health Organisation Guidelines on the Pharmacological Treatment of Persisting Pain in 
Children with Medical Illnesses (2012) has specifically called for research into paediatric pain 
management. [12] 
 
The way forward 
Existing regional paediatric palliative care networks and support organisations (such as Together for 
Short Lives in the UK) should come together to lobby funding bodies to provide finance and 
encourage the academic community to conduct appropriate drug research. Furthermore, the 
regulatory authorities need to understand the needs of these patients and liaison with 
pharmaceutical companies is required to produce suitable products for this group of patients who 
are falling behind in terms of drug discovery and genetic research.  However, some progress has 
been made. There has been a research priorities setting exercise and other support offered from the 
Medicines for Children Research Network Pain & Palliative Care Clinical Studies Group.  The scope of 
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the guidelines for the NICE Guidance for End of Life Care for Infants, Children and Young People will 
include the planning and management of their end of life care and may also include research 
recommendations.  
 
Many medications are administered by family caregivers in the community, yet there is very little 
research data available about the problems they experience.  Our proposed future research will seek 
to examine issues with both prescribing (what medicines are being prescribed and what doses are 
used) and administering of medicines to PPC patients in the community.  We also need more 
information in regard to efficacy and safety of medicines use in this population. 
 
Research is also needed to optimise study designs in PPC research.  A wide range of study designs 
are available but are probably under-used in PPC research. In general, observational studies improve 
our understanding of how drugs are being prescribed and used and are particularly useful in drug 
safety monitoring.[30] Such information can also assist formulation scientists in designing 
appropriate formulations. 
 
Pharmacokinetic studies, coupled with pharmacodynamics data from observational studies or 
published literature data, can develop robust models to guide dosing regimens in different patient 
groups. Such an approach was used as part of the development plans of Buccolam® (buccal 
midazolam) and Ayendi® (intranasal diamorphine) which are designed to be used in children for 
emergency treatments. [31,32]  A similar approach is likely to apply to PPC.  Where there is 
uncertainty in regard to therapeutic interventions, gold standard randomised controlled studies 
(RCTs) are required. Conducting RCTs in this group of children is challenging, particularly in regard to 
maximising recruitment and minimising attrition. Barriers to recruitment include defining eligibility 
criteria, issues around gatekeeping, acceptability of study design and logistical issues around access 
to participants.  A sound ethical framework is required which includes safeguards to ensure minimal 
burden to families.[33] 
 
Children receiving palliative care are the very group for whom we should be doing everything we can 
in order to alleviate their suffering, because when a life is short each day needs to be lived to the 
full. 
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